Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 10, 2001 - Issue 1
Submit an article Journal homepage
178
Views
51
CrossRef citations to date
0
Altmetric
Review

Pharmacological agents for the treatment of urinary incontinence due to overactive bladder

Alan J Wein Division of Urology, University of Pennsylvania Health System, First Floor Rhoads Pavilion, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA. [email protected]
Pages 65-83 | Published online: 24 Feb 2005

Bibliography

  • ANDERSSON K-E: Advances in the pharmacological control of the bladder. Exp. Physiol. (1999) 84:195–213.
  • ••Comprehensive critical review of pharmacologicalmechanisms of bladder over-activity. Discusses potential new targets for therapy of OAB.
  • PAYNE CK: Epidemiology, pathophysiology andevaluation of urinary incontinence and overactive bladder. Urology (1998) 51 (Suppl. 2A):3–10.
  • DE GROAT WC: A neurologic basis for the overactivebladder. Urology (1997) 50:36–52.
  • •Review of central and peripheral nervous control mechanisms of bladder dysfunction.
  • BRADING AF: A myogenic basis for the overactive bladder. Urology (1997) 50:57–67.
  • •Emphasises functional, structural and ultrastructural changes in detrusor muscle that contribute to detrusor instability of UI.
  • BUTERA JA, ARGENTIERI TM: Recent approaches to the treatment of urinary incontinence. Exp. Opin. Ther. Patents (1998) 8:1017–1035.
  • ••Recent review of the major drugs of different mechanisticclasses patented for UI therapy.
  • CHAPPLE CR: Muscarinic receptor antagonists in the treatment of overactive bladder. Urology (2000) 55:33–46.
  • ••Excellent overview of preclinical and clinical pharmacologyof antimuscarinic agents currently used to treat overactive bladder.
  • YAMAGUCHI 0, SHISHIDO K, TAMURA K, OGAWA T, FUJIMURA T, OHTSUKA M: Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle. J. Urol. (1996) 156 (3):1208–1213.
  • •Demonstrates mRNA expression for M2 and M3, but not other muscarinic receptor subtypes, in human detrusor smooth muscle tissue.
  • WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetyl- choline receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol. Exp. Ther. (1995) 273:959–966.
  • •Demonstrates that M2 and M3, but not other muscarinic receptor subtypes, are expressed in detrusor smooth muscle tissue from humans and rodents. Although M2 subreceptors predominate, detrusor smooth muscle contraction occurs mainly via GTP-coupled M3 sub-receptor activation.
  • LONGHURST PA, LEGGETT RE, BRISCOE JA: Characteri-zation of the functional muscarinic receptors in the rat urinary bladder. Br.J Pharmacol (1995) 116:2279–2285.
  • HEGDE SS, CHOPPIN A, BONHAUS D et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol (1997) 120:1409–1418.
  • •Provides evidence suggesting bladder detrusor contraction is mediated directly through stimulation of M3 subreceptors and indirectly via M2 subreceptors that reverse a-adrenoceptor-mediated relaxation.
  • WEIN AJ: Pharmacologic options for the overactive bladder. Urology (1998) 51:43–47.
  • •Concise overview of current and future treatments for OAB, including new therapeutic targets.
  • ANDERSSON K-E: Alphai-adrenoceptors and bladder function. Eur. Urol. (1999) 36:96–102.
  • •Reviews the functions of a-adrenoceptors in control of normal and diseased (UI) bladder. Discusses potential roles of bladder detrusor muscle and neural a-adrenoceptors from experimental clinical and preclinical studies.
  • SCHVVINN DA, PRICE RR: Molecular pharmacology of human alphai-adrenergic receptors: unique features of the alphai.-subtype. Eur. Urol. (1999) 36 (Suppl.
  • ••Excellent review of the function and comparative tissuedistribution of aip-adrenoceptors in different species, including man.
  • MARTIN DJ: Preclinical pharmacology of alphai-adren- oceptor antagonists. Eur. Urol. (1999) 36 (Suppl. 0:35–41.
  • •Emphasises the need to clarify 'uroselective' a-adrenoceptor subtypes, their functions and adrenoceptor antagonist mechanisms in vivo.
  • BRADING AF, MCCOY R, DASS N: Alphai-adrenoceptors in urethral function. Eur. Urol. (1999) 36 (Suppl. 1)74–79.
  • •Reviews current status of ai-adrenoceptors and their roles in control of urethral smooth muscle contraction.
  • UCKERT S, STIEF CG, ODENTHAL KP, BECKER AJ, TRUSSMC, JONAS U: Comparison of the effects of various spasmolytic drugs on isolated human and porcine detrusor smooth muscle. Arzneimittelforschung (1998) 48:836–839.
  • TRUSS M, STIEF CG, UCKERT S, BECKER AJ, FORSSMAN-G,JONAS U: Initial clinical experience with the selective phosphodiesterase (PDE)-1 isoenzyme-inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. J Urol (1997) 157 :Abstract 727.
  • TRUSS MC, UCKERT S, STIEF CG, FORSSMANN WG, JONASU: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol. Res. (1996) 24:129–134.
  • •Demonstrates intracellular phosphodiesterase (PDE) and elevated cyclic AMP mediates detrusor smooth muscle contraction.
  • BURCHER E, ZENG XP, STRIGAS J, SHANG F, MILLARD RJ, MOORE KH: Autoradiographic localization of tachyki-nin and calcitonin gene-related peptide receptors in adult urinary bladder. J Urol. (2000) 163:331–337.
  • •Demonstrated differential expression of receptors for tachykinin (NK-1 and NK-2) and calcitonin gene related peptide in the dome of human urinary bladder from patients with UI.
  • PALEA S, CORSI M, ARTIBANI W, OSTARDO E, PIETRA C: Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J. Pharmacol. Exp. Ther. (1996) 277:700–705.
  • •Presents data for development of novel NK-2 receptor antagonists for treatment of UI.
  • MAGGI CA: Tachykinins and calcitonin gene-relatedpeptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog. Neurobiol (1995) 45:1–98.
  • MAGGI CA: The mammalian tachykinin receptors. Gen.Pharmacol. (1995) 26:911–944.
  • TRIVEDI S, POTTER-LEE L, LI JH et al.: Calciumdependent K-channels in guinea pig and human urinary bladder. Biochem. Biophys. Res. Commun. (1995) 213:404–409.
  • •Demonstrates relaxant effects of potassium channel openers on human and guinea-pig bladder smooth muscle and potential for treatment of bladder over-activity in UI.
  • TRIVEDI S, STETZ SL, POTTER-LEE L et al.: K-channel opening activity of ZD6169 and its analogs: effect on 86Rb efflux and 3H-P1075 binding in bladder smooth muscle. Pharmacology (1995) 50: 388–397.
  • •Preclinical studies in vitro demonstrating the potential use of a novel ATP-sensitive potassium channel opener, ZD-6169, for treatment of UI.
  • HEDLUND H, MATTIASSON A, ANDERSSON KE: Effects ofpinacidil on detrusor instability in men with bladder outlet obstruction. J Urol. (1991) 146:1345–1347.
  • KOMERSOVA K, ROGERSON JW, CONWAY EL et al: Theeffect of lever omakalim (BRL38227) on bladder function in patients with high spinal cord lesions. Br]. Pharmacol. (1995) 39:207–209.
  • HOWE BB, HALTERMAN TJ, YOCHIM CL et al: ZXNECA ZD-6169: a novel KATP channel opener with in vivo selectivity for urinary bladder. J. Pharmacol. Exp. Ther. (1995) 274:884–890.
  • •Preclinical studies in vivo demonstrating the potential use of a novel ATP-sensitive uroselective potassium channel opener, ZD-6169, for treatment of UI.
  • ANDERSSON KE: Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev. (1993) 45:253–308.
  • DAMASER MS, KIM KB, LONGHURST PA, WEIN AJ, LEVINRM: Calcium regulation of urinary bladder function. J Urol. (1997) 157:732–738.
  • •Demonstrates calcium influx via L-type calcium channels in rabbit bladder detrusor smooth muscle are involved in bladder contraction and voiding.
  • FORMAN A, ANDERSSON KE, HENRIKSSON L, RUD T, ULMSTEN U: Effects of nifedipine on the smooth muscle of the human urinary tract in vitro and in vivo. Acta Pharmacol. Toxicol (1978) 43:111–118.
  • ANDERSSON KE: Clinical relevance of some findings in neuro-anatomy and neurophysiology of the lower urinary tract. Clin. Sci. (1986) 70 (Suppl. 14):21S–32S.
  • BO XN, BURNSTOCK G: The effects of Bay K 8644 and nifedipine on the responses of rat urinary bladder to electrical field stimulation, beta, gamma-methylene ATP and acetylcholine. Br. J. Pharmacol (1990) 1 01 :494–498.
  • ZAR MA, IRAVANI MM, LUHESHI GN: Effect of nifedipineon the contractile responses of the isolated rat bladder. J Urol. (1990) 143:835–839.
  • WONG DT, ROBERTSON DW, BYMASTER FP, KRUSHINSKI JH, REID LR: LY227942, an inhibitor of serotonin and norepinephrine uptake: biochemical pharmacology of a potential antidepressant drug. Life Sci. (1988) 43:2049–2057.
  • TESTA R, GUARNERI L, POGGESI E et al: Effect of several 5-hydroxytryptamine(1A) receptor ligands on the micturition reflex in rats: comparison with WAY 100635.1 Pharmacol. Exp. Ther. (1999) 290:1258–1269.
  • •Preclinical pharmacology studies demonstrating inhibitory activity of 5-HT1A receptor antagonists in vivo on volume-induced bladder voiding, increasing bladder capacity without affecting the micturition reflex.
  • WESSLER I, KIRKPATRICK CJ, RACKE K: Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. Pharmacol. Ther. (1998) 77:59–79.
  • •Emphasises the importance of non-neuronal acetylcholine and describes the distribution of a functional non-neural cholinergic system (cholinergic/nicotinic receptors, acetylcholine, choline acetyltransferase) in diverse tissues and cells.
  • GILLBERG PG, SUNDQUIST S, NILVEBRANT L: Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur. J. Pharmacol (1998) 349:285–292.
  • •Suggests selective inhibition of M3 over M2 muscarinic receptors in vitro predisposes for compounds that decrease salivation in vivo; proposes development of M2 receptor antagonists for UI therapy.
  • NILVEBRANT L, ANDERSSON KE, GILLBERG PG, STAHL M,SPARF B: Totter o dine - a new bladder-selective an timuscarinic agent. Eur. J. Pharmacol (1997) 327:195–207.
  • STAHL MM, EKSTROM B, SPARF B, MATTIASSON A, ANDERSSON KE: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor over-activity. Neurourol. Urodyn. (1995)1 4:647–655.
  • •Clinical studies demonstrating favourable efficacy and tolerance of tolterodine.
  • APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 5 0:90–96.
  • •Multicentre clinical studies demonstrating efficacy and superior tolerance of tolterodine versus oxybutynin in patients with overactive bladder.
  • MESSELINK EJ: Treatment of the overactive bladderwith tolterodine, a new muscarinic receptor antago-nist. Br. J Urol. Int. (1999) 83:48–52.
  • GARLEY A et al.: Once-daily tolterodine treatmentsignificantly decreases perception of urgency and urge incontinence episodes in patients with overac-tive bladder. Paper presented at the 21st American UroGynecologic Society Annual Meeting, Hilton Head, SC, October 2000.
  • GUPTA SK, SATHYAN G: Pharmacokinetics of an oralonce-a-day controlled-release oxybutynin formula-tion compared with immediate-release oxybutynin. J Clin. Pharmacol. (1999) 39:289–296.
  • •Demonstrates improved bioavailability and superior tolerance to controlled release oxybutynin versus immediate release oxybutynin.
  • ANDERSSON KE, APPELL R, CARDOZO L et al: Pharma-cological treatment of urinary incontinence. In: Incontinence. Abrams P, Khoury S, Wein A (Eds.), Plymbridge Distributors Ltd., Plymouth, UK (1999):447–486.
  • BIRNS J, MALONE-LEE JG, AND THE OXYBUTYNIN CRSTUDY GROUP: Controlled release oxybutynin maintains efficacy with a 43% reduction in side effects compared with conventional oxybutynin treatment. Neurourol. Urodyn. (1997) 16:429-430. Abstract.
  • NILSSON CG, LUKKARI E, HAARALA M, KIVELA A, HAKONEN T, KIILHOLMA P: Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients. Neurourol. Urodyn. (1997)16:533–542.
  • THUROFF JW, CHARTIER-KASTLER E et al.: Medicaltreatment and medical side effects in urinary inconti-nence in the elderly. World J Urol (1998)16 (Suppl. 1) :S48–61.
  • STOHRER M, BAUER P, GIANNETTI BM, RICHTER R, BURGDORFER H, MURTZ G: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol. mt. (1991) 47:138–143.
  • MADERSBACHER H, STOHRER M, RICHTER R, GIANNETTIBM, MURTZ G: High-dose trospium chloride in therapy of detrusor hyperreflexia. Urologe lAl (1991) 30:260–263.
  • MADERSBACHER H, STOHRER M, RICHTER R, BURGDORFER H, HACHEN HJ, MURTZ G: Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br. J. Urol (1995) 75(4):452–456.
  • •Trospium chloride is better tolerated than oxybutynin in patients with detrusor hyperreflexia.
  • FROHLICH G, BURMEISTER S, WIEDEMANN A, BULITTA M: Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomized clinical test. Arzneimittelforschung (1998) 48:486–491.
  • KACHUR JF, PETERSON JS, CARTER JP, RZESZOTARSKI WJ, HANSON RC, NORONHA-BLOB L: R and S enanti-omers of oxybutynin: pharmacological effects in guinea pig bladder and intestine. J. Pharmacol. Exp. Ther. (1988) 247:867–872.
  • ALABASTER VA: Discovery & development of selective M3 antagonists for clinical use. Life Sci. (1997) 60:1053–1060.
  • •Reviews in vitro and in vivo pharmacology of darifenacin, a selective M3 receptor antagonist with preferential inhibitory effects on the gut and bladder.
  • WALLIS RM, NAPIER CM: Muscarinic antagonists indevelopment for disorders of smooth muscle function. Life Sci. (1999) 64:395–401.
  • ROSARIO DJ, CUTINHA PR, CHAPPLE CR etal.: The effectsof single dose darifenacin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability. Eur. Urol. (1996) 30 (Suppl. 2):240. Abstract.
  • SASAKI Y, HAMADA K, YAMAZAKI C et al: Effect ofNS-21, an an tich olin ergic drug with calcium antago-nistic activity, on lower urinary tract function in a rat model of urinary frequency. Int. J. Urol. (1997) 4:401–406.
  • HAYASHI S, NATSUKAWA T, UKAI Y, YOSHIKUNI Y, KIMURA K: Inhibitory effects of NS-21, a novel drug for urinary incontinence and its active metabolite, RCC-36, on L-type calcium currents in isolated guinea pig detrusor smooth muscle cells. Naunyn Schmiede-bergs Arch. Pharmacol (1997) 355:659–666.
  • •Novel inhibitory effects of temiverine (NS-21) and its metabolite on L-type calcium currents in guinea-pig detrusor muscle; more potent than terodiline.
  • HAMADA K, SASAKI Y, TANIGUCHI N et al.: Anticho- linergic and calcium antagonistic activities of NS-21 contribute to the inhibition of rat urinary bladder contractions. Gen. Pharmacol (1997) 29:771–778.
  • •Dual anticholinergic and calcium antagonist effects of temiverine (NS-21) in vitro and suppression of bladder contraction in vivo.
  • KIMURA Y, FUKUI H, HAMADA K et al.: Effect of the an tich olin ergic drug with calcium antagonistic activity, (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-y1 2-cyclohexy1-2-hydroxy-2-phenylacetate monohydro-chloride monohydrate, on lower urinary tract function in decerebrate dogs. Arzneimittelforschung (1997) 47:182–189.
  • •Superior pharmacological efficacy of temiverine (NS-21) over oxybutynin and terodiline in the dog.
  • KIMURA Y, HAMADA K, FUKUI H et al.: Effect of the an tich olin ergic drug with calcium antagonistic activity, (±)-4-diethylamino-1,1-dimethylbut-2-yn-1-y1 2-cyclohexy1-2-hydroxy-2-phenylacetate monohydro-chloride monohydrate, on lower urinary tract function in rhesus monkeys. Arzneimittelforschung (1997) 47:189–194.
  • •Superior pharmacological efficacy of temiverine (NS-21) over oxybutynin, atropine and verapamil in the monkey.
  • CONNOLLY MJ, ASTRIDGE PS, WHITE EG, MORLEY CA,COWAN JC: Torsades de pointes ventricular tachycardia and terodiline. Lancet (1991) 338:344–345.
  • MIYACHI H, KIYOTA H, UCHIKI H, SEGAWA M: Synthesisand antimuscarinic activity of a series of 4-(1-imidazoly1)-2,2-diphenylbutyramides: discovery of potent and subtype-selective antimuscarinic agents. Bioorg. Med. Chem. (1999) 7:1151–1161.
  • •Describes in vitro and in vivo pharmacology of a novel series of antimuscarinic agents selective for muscarinic subreceptors with preferential inhibition of bladder contrac-tility over salivary gland secretion. Identifies lead compound K-197 for clinical studies.
  • NAITO R, TAKEUCHI M, MORIHIRA K et al.: Selective muscarinic antagonists. II. Synthesis and antimuscar-inic properties of biphenylylcarbamate derivatives. Chem. Pharm. Bull. (Tokyo) (1998) 46:1286–1294.
  • •Describes in vitro and in vivo pharmacology of a novel series of antimuscarinic agents selective for M3 and M1 receptors over M2 receptors; lead compound YM-46303 is more potent than oxybutynin in vivo with preferential activity on bladder over salivary glands.
  • ENGLEMAN EA, ROBERTSON DW, THOMPSON DC, PERRY KW, WONG DT: Antagonism of serotonin 5 -HT1 Areceptors potentiates the increases in ex tracel-lular monoamines induced by duloxetine in rat hypothalamus. J Neurochem. (1996) 66:599–603.
  • THOR KB, KATOFIASC MA: Effects of duloxetine, acombined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J. Pharmacol. Exp. Ther. (1995) 274:1014–1024.
  • •Demonstrates CNS inhibitory activity of duloxetine in irritated but not normal bladder contraction.
  • SHARMA A, GOLDBERG MJ, CERIMELE BJ: Pharmacoki- netics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor./ Clin. Pharmacol (2000) 40:161–167.
  • •Good pharmacokinetic and safety profiles demonstrated for duloxetine in humans.
  • SOMASUNDARAM S, RAFT S, JACOB M et al.: Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut (1997) 40:608–613.
  • MARIOTTO S, MENEGAZZI M, CARCERERI DE PRATT A et al: Protective effect of NO on gastric lesions and inhibition of expression of gastric inducible NOS by flurbiprofen and its nitro-derivative, nitroflurbi-profen. Br. J. Pharmacol (1995) 116:1713–1714.
  • COCKAYNE DA, HAMILTON SG, ZHU QM et al.: Urinarybladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature (2000) 407 (6807):1011–1015.
  • ••Describes P2X3, a novel receptor controlling urinarybladder function; suggests that development of specific P2X3 antagonists may increase bladder volume and decrease voiding frequency in patients with overactive bladder.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.